In a recent development taking place on September 19, 2023, the U.S. Food and Drug Administration (commonly known as FDA or ‘the Agency’) issued a draft guidance, shedding light on its plans regarding Regulatory Considerations for Prescription Drug Use-Related Software (referred to as the ‘Guidance’). Critical to understanding the evolution of FDA’s approach towards digital health products, this draft guidance is a stepping-stone, providing insight into how FDA aims to enforce its drug labeling policies on software products that supplement, expound, or are conceptually associated with the use of a prescription drug.
This move by the FDA signals its intent to keep pace with the rapidly expanding role of technology in the health sector. As the regulation framework for digital health products continues to evolve, it is imperative that legal professionals keep themselves up-to-date. Particularly, those working in corporations dealing with drug production, legal firms handling cases relevant to health technology, and other similar entities need to tune their understanding with this new direction in which the regulatory landscape is developing.
The Guidance published by the Agency is intended to offer additional clarity on the FDA’s expectations for labeling prescription drug use-related software. In a broader context, it aims to endorse safe usage and ensure that potential users attain a comprehensive understanding of these products, their characteristics, and their implications on the handling and usage of prescription drugs.